Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Oct 15, 2006 (Vol. 26, No. 18)

BioBOOM BioTech Blog

  • A lot of useful info
  • Awful design
Here is a blog worth mentioning that covers biotechnology. Apparently subscribing to the notion that if the word blog appears in the title, the layout of the site must be rather chaotic, BioBOOM still brings a lot to the table. Starting with a stock ticker at the top of the opening page and recent stories beneath it, BioBOOM sprawls with links to Websites, meeting, and professional organization below that, followed by another section near the bottom called Up to Date BioBOOM BioTech News. If that wasn’t enough, beneath that is a set of links to the latest medical news. Wait, I’m not done—after that, there is another section of links to other blogs. Compounding the organizational obstacles, each section has a style and color scheme inconsistent with the previous one. It’s all too bad, because there is a tremendous amount of useful info here. Hopefully BioBOOM will hit it big and be able to afford to hire a site designer.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »